Search Results

Aquavit Pharmaceuticals, Inc. announced that the company’s technology patent for “Methods for Delivering Bioactive Compositions and Formulations Using Microchannel Delivery Device” has been approved for publishing by the World Intellectual Property Organization.

Aquavit Holdings (Aquavit), a biotechnology company focused on the development of botulinum toxin applications, announced today that it has filed an Investigational New Drug Application with the FDA for its flagship intradermal injection of botulinum toxin, Dermatox™ (aqubotulinumtoxinA).

Aquavit Holdings announced that it has received FDA clearance to initiate clinical trials for DTX-023 and DTX-024, following its submission of Investigational New Drug Applications.

Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.

Aquavit Pharmaceuticals, Inc. announced that it has appointed Senior Vice President Timothy Sherwood as Chief Operating Officer.

Aquavit Pharmaceuticals, Inc. announced that it has submitted its IND package for a new botulinum toxin to the FDA for approval.

Announces its IND Submissions to FDA for Aquatox™ at the Annual American Academy of Dermatology 2023

Aquavit Pharmaceuticals, Inc. (Aquavit), a biotechnology company focused on the development of a first-of-its-kind microchannel drug delivery technology, recently announced that the company received a notice of allowance through the USPTO’s Fast-Track Prioritized Examination Pilot Program (PEPP) for the application of the company’s proprietary technology for self-injectable Covid 19 vaccination (AQV-1122.)

Aquavit Pharmaceuticals, Inc. (“Aquavit”) won a default judgement against counterfeiter in the United States District Court for the Southern District of New York in a civil action against Global Medi Products, a South Korean company.

U.S. patent number 10,980,865 [Application Number 14/909,954] was granted to Aquavit Pharmaceuticals, Inc. for direct application system and method for the delivery of bioactive compositions and formulations .